DIS vs LLY: Which Is the Better Buy?
Side-by-side comparison of The Walt Disney Company and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
The Walt Disney Company · Communication Services
$101.31
+66.6% upside to fair value
Grade B
VS
Eli Lilly and Company · Healthcare
$934.34
+98.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+98.6%).
DIS trades at a lower forward P/E
(14.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DIS |
LLY |
| Current Price |
$101.31 |
$934.34 |
| Fair Value Estimate |
$168.80 |
$1,855.91 |
| Upside to Fair Value |
+66.6%
|
+98.6%
|
| Market Cap |
$179.5B |
$882.8B |
| Forward P/E |
14.8x
|
33.1x
|
| EV / EBITDA |
11.4x
|
27.9x
|
| Price / Sales |
1.9x
|
12.2x
|
| Price / FCF |
25.4x
|
65.0x
|
| Revenue Growth YoY |
+5.2%
|
+55.5%
|
| Gross Margin |
37.3%
|
82.7%
|
| Operating Margin |
14.2%
|
46.3%
|
| Return on Equity |
11.3%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.93%
|
1.54%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
The Walt Disney Company operates as a diversified entertainment giant with strong competitive advantages from its vast intellectual property portfolio, global theme parks, and growing direct-to-consumer streaming platforms. The company demonstrates medium business quality with a durable moat supported by iconic brands and infrastructure, but faces execution risks in streaming profitability and pa…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
DIS |
LLY |
| Zone Low |
$126.60 |
$1,391.93 |
| Zone High |
$143.48 |
$1,577.52 |
| In Buy Zone? |
Yes
|
Yes
|